The test is performed on the company's AmpiProbe platform, and the approval expands Enzo's offering of infectious disease tests in New York.
Medcis Pathlabs and its associates and attendees will buy Co-Diagnostics' tests for hepatitis B, hepatitis C, HIV, and human papillomavirus.
Hologic CEO Steve MacMillan said that the deal is so compelling that the firm needed to do it now.
The test enables donor screening laboratories to use PCR-based diagnostic technology to screen donated blood and plasma.
Professional, molecular, and tissue diagnostics sales continued to grow during the first three quarters, while diabetes care sales remained in decline.
In Nature this week: modified CRISPR approach changes single nucleotides, new salmon genome assembly, and more.
Roche's molecular diagnostics business, which makes up 17 percent of its overall diagnostics sales, grew 11 percent, driven by virology testing and sequencing.
The virus, known as HPgV-2, was detected in blood samples from individuals with concurrent hepatitis C virus infections.
It's the first approved test to feature the firm's proprietary AmpiProbe nucleic acid amplification and detection platform.
In PNAS this week: decreased DOCK4 expression in myelodysplastic syndromes plus anemia, hepatitis A evolution, and more.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.